Guatemala
Tuberculosis profile
| High HIV burden |
Population  2013 15 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.25 (0.24–0.26) 1.6 (1.6–1.7)
Mortality (HIV+TB only) 0.41 (0.34–0.49) 2.6 (2.2–3.2)
Prevalence  (includes HIV+TB) 17 (8.6–28) 110 (56–183)
Incidence  (includes HIV+TB) 9.2 (8.2–10) 60 (53–67)
Incidence (HIV+TB only) 0.91 (0.81–1) 5.9 (5.2–6.6)
Case detection, all forms (%) 36 (32–40)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 3 (1.8–4.6) 26 (20–34)
MDR-TB cases among notified pulmonary
TB cases
85 (51–130) 62 (46–79)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 2 849   175
Pulmonary, clinically diagnosed 0   0
Extrapulmonary 287   0
       
Total new and relapse 3 311    
Previously treated, excluding relapses 58    
Total cases notified 3 369    
Among 2 196 new cases:
41 (2%) cases aged under 15 years; male:female ratio: 1.3
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 5 (<1%) 126 (54%) 262
Laboratory-confirmed RR-/MDR-TB cases     51
Patients started on MDR-TB treatment     28
TB/HIV 2013 Number (%)
TB patients with known HIV status 2 703 (80)
HIV-positive TB patients 267 (10)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0 (0)
HIV-positive TB patients on antiretroviral therapy (ART) 242 (91)
HIV-positive people screened for TB    
HIV-positive people provided with IPT 316  
Treatment success rate (%)
New cases registered in 2012 88
Previously treated cases registered in 2012 71
HIV-positive TB cases, all types, registered in 2012 71
RR-/MDR-TB cases started on second-line treatment in 2011 70
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.7
Culture (per 5 million population) 3.9
Drug susceptibility testing (per 5 million population) 0.3
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) <1
% Funded domestically 1454%
% Funded internationally 347%
% Unfunded <1%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-03-29 Data: www.who.int/tb/data